ATE297202T1 - Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration - Google Patents
Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregenerationInfo
- Publication number
- ATE297202T1 ATE297202T1 AT98950843T AT98950843T ATE297202T1 AT E297202 T1 ATE297202 T1 AT E297202T1 AT 98950843 T AT98950843 T AT 98950843T AT 98950843 T AT98950843 T AT 98950843T AT E297202 T1 ATE297202 T1 AT E297202T1
- Authority
- AT
- Austria
- Prior art keywords
- nerve regeneration
- promote nerve
- immune suppressive
- hsp90
- receptor complexes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/956,691 US5968921A (en) | 1997-10-24 | 1997-10-24 | Compositions and methods for promoting nerve regeneration |
PCT/US1998/020658 WO1999021552A1 (en) | 1997-10-24 | 1998-10-02 | Use of non-immunosuppressive compounds for promoting nerve regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE297202T1 true ATE297202T1 (de) | 2005-06-15 |
Family
ID=25498557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98950843T ATE297202T1 (de) | 1997-10-24 | 1998-10-02 | Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration |
Country Status (8)
Country | Link |
---|---|
US (5) | US5968921A (de) |
EP (1) | EP1024806B1 (de) |
JP (1) | JP2001520995A (de) |
AT (1) | ATE297202T1 (de) |
AU (1) | AU759011B2 (de) |
CA (1) | CA2308216C (de) |
DE (1) | DE69830509T2 (de) |
WO (1) | WO1999021552A1 (de) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2287387C (en) * | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
US6852496B1 (en) | 1997-08-12 | 2005-02-08 | Oregon Health And Science University | Methods of screening for agents that promote nerve cell growth |
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
IL142165A0 (en) * | 1998-10-02 | 2002-03-10 | Kosan Biosciences Inc | Polyketide synthase enzymes and recombinant dna constructs therefor |
US20040120891A1 (en) | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
WO2000061578A1 (en) * | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
US7238682B1 (en) | 1999-04-09 | 2007-07-03 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases |
US6734211B1 (en) | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
EP1200078A4 (de) * | 1999-07-09 | 2004-06-30 | Univ Oregon Health & Science | Zusammenstellungen und verfahren zur förderung der nervenregenerierung |
US6979574B1 (en) * | 1999-08-06 | 2005-12-27 | Institut Fuer Diagnostik Forshung Gmbh | Process for detecting binding reactions with use of the measurement of the relaxation of the double refraction of magnetic particles |
EP1225906B1 (de) * | 1999-08-17 | 2008-11-19 | The Trustees Of The University Of Pennsylvania | Mechanisch verlängerte neuronale zellen und methoden zur herstellung und verwendung dieser zellen |
US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
US6818643B1 (en) | 1999-12-08 | 2004-11-16 | Bristol-Myers Squibb Company | Neurotrophic bicyclic diamides |
ATE526019T1 (de) * | 2000-07-28 | 2011-10-15 | Sloan Kettering Inst Cancer | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
KR100850727B1 (ko) | 2000-11-02 | 2008-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90에 결합하기 위한 소분자 조성물 |
MXPA03007856A (es) * | 2001-03-30 | 2003-12-04 | Us Health | Derivado de geldanamicina y metodo de usarlo para tratar cancer. |
EP1387678A1 (de) * | 2001-05-03 | 2004-02-11 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Verbindungen,die hsp90 stimulieren und hsp70 und hsp40 inhibieren, und deren verwendung zur prophylaxis und behandlung von krankheiten, die mit protein aggregation und mit amyloid bildung verbunden sind |
JP2004529188A (ja) * | 2001-05-23 | 2004-09-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 上昇に関連した癌の治療法 |
US7169564B1 (en) * | 2001-06-26 | 2007-01-30 | Anaderm Research Corporation | FKBP51/52 and CyP40-mediated mammalian hair growth |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
US7241890B2 (en) * | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
AU2003217393B8 (en) * | 2002-02-08 | 2009-06-25 | Conforma Therapeutics Corporation | Ansamycins having improved pharmacological and biological properties |
CA2481683A1 (en) * | 2002-04-10 | 2003-10-23 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
WO2004022156A2 (en) * | 2002-09-04 | 2004-03-18 | Washington University | Methods for treating central nervous system damage |
US20060148776A1 (en) * | 2003-03-13 | 2006-07-06 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
WO2005028434A2 (en) * | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
ES2409351T3 (es) | 2003-12-23 | 2013-06-26 | Infinity Discovery, Inc. | Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer |
CA2559652C (en) * | 2004-03-15 | 2017-02-14 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 in treating cancer |
US20050267087A1 (en) * | 2004-04-28 | 2005-12-01 | Vassiliki Poulaki | Inflammatory eye disease |
WO2006004201A1 (ja) * | 2004-07-01 | 2006-01-12 | Eisai R & D Management Co., Ltd. | 神経再生促進剤 |
US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
US7544171B2 (en) * | 2004-10-22 | 2009-06-09 | General Patent Llc | Methods for promoting nerve regeneration and neuronal growth and elongation |
JP4954083B2 (ja) * | 2004-11-18 | 2012-06-13 | シンタ ファーマスーティカルズ コーポレイション | Hsp90活性を調節するトリアゾール化合物 |
DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
US7988648B2 (en) * | 2005-03-04 | 2011-08-02 | General Patent, Llc | Pancreas regeneration treatment for diabetics using extracorporeal acoustic shock waves |
CA2602257A1 (en) * | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors |
AU2006235105A1 (en) * | 2005-04-07 | 2006-10-19 | Conforma Therapeutics Corporation | Phospholipid-based pharmaceutical formulations and methods for producing and using same |
NZ565953A (en) * | 2005-07-27 | 2012-01-12 | Univ Florida | Small compounds that correct protein misfolding and uses thereof |
NZ565954A (en) * | 2005-07-27 | 2012-03-30 | Univ Florida | Use of heat shock inducing compound and an agent that increases stem cell mobilization int he manufacture of a medicament to treat ocular disease |
JP5118039B2 (ja) | 2005-08-18 | 2013-01-16 | シンタ ファーマシューティカルズ コーポレーション | Hsp90活性を調節するトリアゾール化合物 |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
WO2007064926A2 (en) * | 2005-12-01 | 2007-06-07 | Conforma Therapeutics Corporation | Compositions containing ansamycin |
US8658633B2 (en) * | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
WO2007139960A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
BRPI0713637A2 (pt) | 2006-06-12 | 2012-10-23 | Sunesis Pharmaceuticals Inc | composição, composto, e , método para o tratamento de cáncer |
US20080063642A1 (en) * | 2006-08-02 | 2008-03-13 | Adelman Daniel C | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
CL2008000629A1 (es) * | 2007-03-01 | 2008-08-29 | Chugai Pharmaceutical Co Ltd | Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer. |
DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
DE102007032739A1 (de) | 2007-07-13 | 2009-01-15 | Merck Patent Gmbh | Chinazolinamidderivate |
KR100891313B1 (ko) | 2007-08-17 | 2009-03-31 | (주) 제노텍 | 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법 |
DE102007041116A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-Dihydro-isoindolderivate |
EP3141250A1 (de) * | 2007-10-22 | 2017-03-15 | Sunesis Pharmaceuticals, Inc. | Verfahren zur verwendung von (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carbonsäure in einer kombinationstherapie |
WO2010053487A1 (en) * | 2008-11-07 | 2010-05-14 | Cydex Pharmaceuticals, Inc. | Composition containing sulfoalkyl ether cyclodextrin and latanoprost |
DE102008061214A1 (de) | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
EP2471918A4 (de) | 2009-09-29 | 2013-06-05 | Takeda Pharmaceutical | Screening-verfahren |
DE102009054302A1 (de) | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
DE102010046837A1 (de) | 2010-09-29 | 2012-03-29 | Merck Patent Gmbh | Phenylchinazolinderivate |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ngf組成物およびその使用 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
EP2780010A1 (de) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Kombinationstherapie aus hsp90-inhibitoren mit braf-inhibitoren |
US10064938B2 (en) | 2016-03-11 | 2018-09-04 | University Of Wyoming | Localized immunosuppression of allografts for peripheral nerve repair |
US11389371B2 (en) | 2018-05-21 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
US11458069B2 (en) | 2016-04-18 | 2022-10-04 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to treat medical conditions using reflexology zones |
US11389373B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to prevent or treat opioid addiction |
US11389372B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
US11389370B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Treatments for blood sugar levels and muscle tissue optimization using extracorporeal acoustic shock waves |
WO2018075192A1 (en) | 2016-10-19 | 2018-04-26 | Spectrum Brands, Inc. | Portable steam generator base for iron |
JP2021530507A (ja) | 2018-07-18 | 2021-11-11 | マンザニータ ファーマシューティカルズ,インク. | 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 |
US11376219B2 (en) | 2018-07-30 | 2022-07-05 | University Of Wyoming | Localized immunosuppression of allografts for peripheral nerve repair |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5026381A (en) * | 1989-04-20 | 1991-06-25 | Colla-Tec, Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
WO1992004370A1 (en) * | 1990-08-29 | 1992-03-19 | Vertex Pharmaceuticals Incorporated | Modified di- and tripeptidyl immunosuppressive compounds |
DE69116563T3 (de) * | 1990-09-21 | 2006-07-06 | The Salk Institute For Biological Studies, La Jolla | Durch protoonkogenischen Proteinkomplex AP-1 kontrollierte Verfahren |
EP0584217A1 (de) * | 1991-05-08 | 1994-03-02 | Vertex Pharmaceuticals Incorporated | RFKBP: eine neue Prolylisomerase und Rapamycin/FK506 bindendes Protein |
US5620971A (en) | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
CA2102180C (en) * | 1991-05-09 | 2002-07-23 | David M. Armistead | Novel immunosuppressive pyrrolidine/piperidine/azepane-2-carboxylic acid derivatives |
WO1992021213A1 (en) | 1991-05-15 | 1992-11-26 | Videonics Incorporated | An improved digital video image adjusting circuit and a method therefor |
MX9202466A (es) * | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
WO1993007269A1 (en) * | 1991-10-11 | 1993-04-15 | Vertex Pharmaceuticals Incorporated | ISOLATION OF AN Mr 52,000 FK506 BINDING PROTEIN AND MOLECULAR CLONING OF A CORRESPONDING HUMAN cDNA |
WO1993023548A2 (en) * | 1992-05-20 | 1993-11-25 | Vertex Pharmaceuticals Incorporated | METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF |
US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
US5354845A (en) * | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
US5612350A (en) * | 1993-11-30 | 1997-03-18 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
US5543423A (en) | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
CA2218523A1 (en) * | 1995-05-02 | 1996-11-07 | William J. Welch | Inducement of thermotolerance with benzoquinonoid ansamycins |
US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
JP3089350B2 (ja) * | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | シクロフィリンロタマーゼ活性の阻害剤 |
IL125031A0 (en) | 1995-12-22 | 1999-01-26 | Lilly Co Eli | Method for treating depression |
US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
-
1997
- 1997-10-24 US US08/956,691 patent/US5968921A/en not_active Expired - Fee Related
-
1998
- 1998-10-02 CA CA002308216A patent/CA2308216C/en not_active Expired - Fee Related
- 1998-10-02 DE DE69830509T patent/DE69830509T2/de not_active Expired - Fee Related
- 1998-10-02 EP EP98950843A patent/EP1024806B1/de not_active Expired - Lifetime
- 1998-10-02 AT AT98950843T patent/ATE297202T1/de not_active IP Right Cessation
- 1998-10-02 AU AU96783/98A patent/AU759011B2/en not_active Ceased
- 1998-10-02 JP JP2000517710A patent/JP2001520995A/ja active Pending
- 1998-10-02 WO PCT/US1998/020658 patent/WO1999021552A1/en active IP Right Grant
-
1999
- 1999-04-07 US US09/288,061 patent/US6210974B1/en not_active Expired - Fee Related
-
2001
- 2001-04-02 US US09/825,243 patent/US6641810B2/en not_active Expired - Fee Related
-
2003
- 2003-09-04 US US10/656,701 patent/US6881409B2/en not_active Expired - Fee Related
-
2005
- 2005-04-18 US US11/109,463 patent/US20050226871A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050226871A1 (en) | 2005-10-13 |
EP1024806A1 (de) | 2000-08-09 |
US6881409B2 (en) | 2005-04-19 |
DE69830509T2 (de) | 2005-11-03 |
US5968921A (en) | 1999-10-19 |
US6641810B2 (en) | 2003-11-04 |
EP1024806B1 (de) | 2005-06-08 |
CA2308216C (en) | 2009-09-01 |
US20040063610A1 (en) | 2004-04-01 |
WO1999021552A1 (en) | 1999-05-06 |
AU9678398A (en) | 1999-05-17 |
AU759011B2 (en) | 2003-04-03 |
US20020086015A1 (en) | 2002-07-04 |
DE69830509D1 (de) | 2005-07-14 |
JP2001520995A (ja) | 2001-11-06 |
US6210974B1 (en) | 2001-04-03 |
CA2308216A1 (en) | 1999-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE297202T1 (de) | Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration | |
EP0724456A4 (de) | Antikörper gegen cd40 | |
ATE208494T1 (de) | Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung | |
EP0975374A4 (de) | Radiometall-bindende peptide analoge | |
DE69942981D1 (de) | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie | |
ATE232545T1 (de) | Rezeptor spezifische atrio-natriuretische peptide | |
AU2001263215A1 (en) | Method for treating cartilage disorders | |
ZA951974B (en) | Bradykinin antagonist peptides incorporating N-subsituted glycines | |
TR199900694T2 (xx) | �nsulin C-peptitleri. | |
WO1997009998A3 (en) | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors | |
DE69408668D1 (de) | Benz(b)azepin-2,5-dione verwendbar in der behandlung neurodegenerativer störungen | |
WO1994023034A3 (en) | Variant insulin-like growth factor I receptor subunits and methods for use thereof | |
ZA961450B (en) | A process for the preparation of factor ix from biological sources | |
DE69718146D1 (de) | At1 rezeptor antagonist zur anregung von apoptosis | |
WO2002099438A3 (en) | Modulation of steroid hormone uptake | |
GB9726630D0 (en) | Kv2.1 Antagonists | |
EP0627934A4 (de) | Frühes antigen für autoimmun-diabete. | |
Stevenson | Zen Suite | |
HUP9903273A3 (en) | Anti-human mp52 monoclonal antibody | |
MX9701999A (es) | Un metodo para estructurar el procesamiento de llamadas y un sistema de conmutacion de procesamientode llamadas para telefonia. | |
UA22181A (uk) | Спосіб лікуваhhя гіпогалактії |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |